UK becomes first country to authorise anti-Covid pill

Britain has granted conditional authorisation to the only pill shown to successfully treat Covid-19 so far. 

It became the first country on Thursday to approve the treatment from drugmaker Merck, although it wasn't immediately clear how quickly the pill would be available.

The pill was licensed for adults 18 and older who have tested positive for Covid-19 and have at least one risk factor for developing severe disease, such as obesity or heart disease. 

Patients with mild-to-moderate Covid-19 would take four pills of the drug, known as molnupiravir, twice a day for five days.

An antiviral pill that reduces symptoms and speeds recovery could prove groundbreaking, easing caseloads on hospitals and helping to curb outbreaks in poorer countries with fragile health systems. 

READ MORE: US panel endorses Pfizer Covid vaccine for younger children

Two-pronged approach

It would also bolster the two-pronged approach to the pandemic: treatment, by way of medication, and prevention, primarily through vaccinations.

Molnupiravir is also pending review with regulators in the US, the European Union and elsewhere. 

The US Food and Drug Administration announced last month it would convene a panel of independent experts to scrutinise the pill's safety and effectiveness in late November.

Initial supplies will be limited. 

Merck has said it can produce 10 million treatment courses through the end of the year, but much of that supply has already been purchased by governments worldwide.

In October, UK officials announced they secured 480,000 courses of molnupiravir and expected thousands of vulnerable Britons to have access to the treatment this winter via a national study.

READ MORE: US signs $1.2M deal to procure 1.7 million courses of Merck's Covid-19 pill

'Historic day'

“Today is a historic day for our country, as the UK is now the first country in the world to approve an antiviral that can be taken at home for Covid-19," British health secretary Sajid Javid said.

“We are working at pace across the government and with the NHS to set out plans to deploy molnupiravir to patients through a national study as soon as possible," he said in a statement, referring to the UK's National Health Service.

Doctors said the treatment would be particularly significant for people who don't respond well to vaccination.

Merck announced preliminary results last month showing its drug cut hospitalisations and deaths by half among patients with early Covid-19 symptoms. 

The results haven't yet been peer reviewed or published in a scientific journal.